GHRS

17.5305.55%
MF

Michael Forer

Independent Vice Chairman

Mr. Michael Forer, L.L.B, has been a Independent Vice Chairman and Independent Non-Executive Director at GH Research PLC since March 2022 and December 2020 respectively. Mr. Forer had been General Counsel of ADC Therapeutics SA since October 1, 2020 until 2022. He previously served as Managing Director at the Rosetta Capital Limited. Mr. Forer is a Co-Founder and Partner of Rosetta Capital Limited in 2001. He has experience in the life science sector as an entrepreneur, advisor and Investor, initially at Rothschild Asset Management. Previously, Mr. Forer was the Managing Director for the investment activities of Auven Therapeutics Holdings L.P. from 2008 to 2015. Mr. Forer served as Non-Executive Director of ADC Products (UK) Limited until 2022. He served as Executive Vice President of ADC Therapeutics SA. since June 2015 until 2022 and served as its Chief Financial Officer May 2016 until May 2020. He served as Director at Rose Pharma A/S. Mr. Forer served as Chief Executive Officer at ADC Therapeutics Sarl since June 06, 2011 until June 22, 2015. He previously served at Rothschild Asset Management Inc. He previously served as Co-Founder at BioScience Managers Limited. Mr. Forer joined Celtic Therapeutics on December 19, 2008. At Rosetta, he led its secondary investment strategy to acquire portfolios of private equity investments in primarily therapeutics-focused companies in Europe and North America, including backing from leading institutional Investors. Mr. Forer was also responsible for the origination and execution of numerous advisory transactions for international private equity backed drug development and medical technology companies. He was a Co-Founder at BioScience Managers Limited, which he co-founded in February 2001. Prior to co-founding Rosetta, from 1998 to 2001, Mr. Forer was a Member of the Life Science private equity investment team at Rothschild Asset Management, where his activities included origination, execution and management of private equity investments in the global life science sector. From 2009 to 2013, Mr. Forer was a Board Member and Executive Director of Spirogen. Mr. Forer joined Rothschild to assist with the launch of a dedicated Canadian fund and to be a Member of the multidisciplinary team responsible for the management of the two international funds Biotechnology Investments Limited (BIL) and the International Biotechnology Trust (IRT). Prior to joining Rothschild, from 1992 to 1998, Mr. Forer was a co-Founder of ECI Medical Technologies Inc. where he was responsible for raising significant venture capital and private finance, the scale up of patented technology into an FDA approved 24/7 manufacturing facility, international product development and distribution initiatives with leading multinational companies and the recruitment of professional management. He subsequently assisted the financiers of ECI in the successful turnaround of NeoCon International Inc. from 1997 to 1998. He served as Vice Chairman of ADC Therapeutics SA from June 2015 to June 15, 2023 and had been its Board Observer since June 15, 2023. Mr. Forer is a past Board Member of Medical Devices Canada. He was called to the Bar of the Law Society of Upper Canada after being at Ogilvy Renault, specializing in the areas of business, transactional and securities law. He has held Board roles in Aditech, KDev Investments, Resonant Medical. Mr. Forer did his Bachelor of Laws from the University of British Columbia in 1990, an International Business Diploma from the University of Copenhagen in 1987 and a B.A. in Economics from the University of Western Ontario in 1986.

Positions